Champions ONCOLOGY, Inc. (CSBR) intrinsic value & 10-year financials

Champions ONCOLOGY, Inc. (CSBR) has a Graham intrinsic value of $10.96 per share. At $4.70 on Oct 17, 2026, the stock trades 57% below that value. Over the last 10 fiscal years revenue grew 16.2% a year to $59.4M, with an average return on invested capital of -91.9%.

Graham intrinsic value
$10.96
Share price (Oct 17, 2026)
$4.70
Price vs Graham value
57% below
Market cap
$65.0M
Revenue (FY2026)
$59.4M
Revenue growth (10-yr CAGR)
16.2%
ROIC (10-yr avg)
-91.9%
Free cash flow (FY2026)
-$5.0M

CSBR 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2026 $59.4M -$1.2M -$0.08 -$5.0M -1.9% -295.3%
FY2025 $56.9M $4.7M $0.33 $7.0M 8.0% 1828.5%
FY2024 $50.2M -$7.3M -$0.54 -$7.0M -14.7% -395.8%
FY2023 $53.9M -$5.3M -$0.39 $1.1M -9.8% -101.0%
FY2022 $49.1M $548.0K $0.04 $4.1M 1.2% 5.7%
FY2021 $41.0M $362.0K $0.02 -$5.0M 0.9% 5.2%
FY2020 $32.1M -$2.0M -$0.17 $685.0K -5.6% 422.7%
FY2019 $27.1M $128.0K $0.01 $1.0M 1.0% -15.0%
FY2018 $20.2M -$1.5M -$0.13 -$2.5M -6.7% -672.0%
FY2017 $15.4M -$6.9M — -$3.6M -44.2% -1702.2%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

CHAMPIONS ONCOLOGY, INC. is a consistent compounder, expanding top-line revenue at 16.2% annually over the past decade.

CHAMPIONS ONCOLOGY, INC. has historically struggled to out-earn its cost of capital, averaging just -11.2% ROIC.

CHAMPIONS ONCOLOGY, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, CHAMPIONS ONCOLOGY, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $10.96 per share.

CSBR stock: frequently asked questions

What is the intrinsic value of Champions ONCOLOGY, Inc. (CSBR) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 15.0% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, CSBR's intrinsic value is about $10.96 per share.

Is CSBR stock undervalued?

At $4.70 (close on Oct 17, 2026), CSBR trades 57% below its Graham value of $10.96. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Champions ONCOLOGY, Inc. grown?

Revenue went from $15.4M in fiscal 2017 to $59.4M in fiscal 2026, a compound annual growth rate of 16.2%. Net income was -$1.2M in fiscal 2026.

Does Champions ONCOLOGY, Inc. generate free cash flow?

Champions ONCOLOGY, Inc. generated -$5.0M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2026. Free cash flow was positive in 5 of the last 10 reported years.

What is CSBR's return on invested capital?

Average ROIC over the last 10 fiscal years was -91.9%, and average return on equity was -262.0%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this CSBR data come from?

From Champions ONCOLOGY, Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Jul 27, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar biological products stocks